We tested our hypothesis by titrating the effects of bortezomib on LLC cell NF-κB activation and proliferation and by conducting parallel experiments of intrapleural and subcutaneous introduction of this tumor into syngeneic mice. Here, NFKB1 is linked to neoplasm.